Gisev家庭辦公室

2020年10月23日

Solarea生物宣布係列S2G企業領導的融資和大膽Capital Partners Solarea生物,位於劍橋的生物技術公司,開發microbial-based解決方案來幫助人類健康,今天宣布它已經籌集了11.2美元的一係列S2G企業領導的融資和大膽Capital Partners,以及海盜的持續投資全球和額外投資Gisev家庭辦公室作為一個集團的投資者。Solarea迅速建立了一個平台來確認地址新型產品廣泛的慢性健康疾病。公司產生了一個龐大而獨特的數據庫的完整基因組序列的微生物來源於健康的食物。使用計算方法,Solarea產生協同組合的細菌,真菌和生命起源以前的纖維具有強大的抗炎功能來解決特定慢性病困擾很多人。這些已經在臨床驗證體外和體內小鼠模型。Solarea的第一個應用程序旨在幫助代謝過程的膳食管理,導致骨量減少和絕經後婦女的骨質疏鬆症。這提供了一種自然的解決方案來改善婦女的健康和幸福。肌肉骨骼疾病,包括骨質疏鬆症,骨量減少,骨關節炎,是全球殘疾的主要原因。在美國,approximately 10 million Americans are currently living with osteoporosis or osteopenia, and one in three women over age 50 will experience an osteoporosis related fracture. Tragically, hip fractures have a one-year mortality rate of 30% and a two-year of close to 56%. Solarea believes a natural, microbial-based solution will have a positive impact on the quality of life of millions of women worldwide who are at risk for these musculoskeletal disorders and aid in improving health outcomes. Solarea will use the proceeds from its Series A fundraise to advance its musculoskeletal product, SBD111, through a clinical proof of activity trial as well as continue the discovery and development of its ongoing pipeline of microbial-based products. “We are very excited for Solarea to enter this stage with such a great team of investors. Our team is completely aligned in our view of the future of food as medicine and the process to develop and commercialize novel microbial-based solutions. We see a clear link between analyzing healthy foods and creating new products to improve the lives of patients in need,” says Gerardo V Toledo, Solarea’s CEO and Co-founder. Matthew Walker, Managing Director at S2G Ventures notes: “Solarea is developing products that combat diseases of inflammation through the gut microbiome in a way that works synergistically with the body and is backed by rigorous preclinical sudies. As we continue to see a convergence between food and medicine, we’re delighted to partner with Bold Capital, Viking Global, and the Gisev Family Office to help support this exceptional team in their mission to use food-based tools to improve human health.” Neal Bhadkamkar, General Partner at Bold comments: “Solarea is a quintessential Bold portfolio company – a passionate and deeply knowledgeable team seeking to create meaningful societal impact by harnessing the power of exponential technologies, in this case sequencing and computational biology. We are eager to see Solarea’s first products get to market and improve the bone health of millions of women and men worldwide. Bold Capital, Viking and other early investors stepped in to support Solarea as it left the Illumina Accelerator two years ago. We are thrilled to see the company take this next step in its journey with S2G Ventures and Gisev Family Office joining the investor group.” Sign Up to Free Newsletter The Microbiome Drug Database